ATE509106T1 - Modifizierte lösliche fgf-rezeptor-fc-fusionen mit verbesserter biologischer aktivität - Google Patents

Modifizierte lösliche fgf-rezeptor-fc-fusionen mit verbesserter biologischer aktivität

Info

Publication number
ATE509106T1
ATE509106T1 AT07866627T AT07866627T ATE509106T1 AT E509106 T1 ATE509106 T1 AT E509106T1 AT 07866627 T AT07866627 T AT 07866627T AT 07866627 T AT07866627 T AT 07866627T AT E509106 T1 ATE509106 T1 AT E509106T1
Authority
AT
Austria
Prior art keywords
fusions
biological activity
fgf receptor
improved biological
modified soluble
Prior art date
Application number
AT07866627T
Other languages
English (en)
Inventor
Mark Nesbit
Beatrice Cameron
Francis Blanche
Sylvie Sordello
Celine Nicolazzi
Marc Trombe
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39431092&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE509106(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE509106T1 publication Critical patent/ATE509106T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT07866627T 2006-11-28 2007-11-28 Modifizierte lösliche fgf-rezeptor-fc-fusionen mit verbesserter biologischer aktivität ATE509106T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06291824 2006-11-28
EP07290042 2007-01-11
PCT/IB2007/004354 WO2008065543A2 (en) 2006-11-28 2007-11-28 Modified soluble fgf receptor fc fusions with improved biological activity

Publications (1)

Publication Number Publication Date
ATE509106T1 true ATE509106T1 (de) 2011-05-15

Family

ID=39431092

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07866627T ATE509106T1 (de) 2006-11-28 2007-11-28 Modifizierte lösliche fgf-rezeptor-fc-fusionen mit verbesserter biologischer aktivität

Country Status (33)

Country Link
US (3) US8119770B2 (de)
EP (1) EP2092069B2 (de)
JP (1) JP2010510801A (de)
KR (1) KR20090102769A (de)
AR (1) AR063975A1 (de)
AT (1) ATE509106T1 (de)
AU (1) AU2007326985C1 (de)
BR (1) BRPI0719290A2 (de)
CA (1) CA2668932A1 (de)
CL (1) CL2007003411A1 (de)
CO (1) CO6190564A2 (de)
CR (1) CR10777A (de)
CY (1) CY1112435T1 (de)
DK (1) DK2092069T3 (de)
EA (1) EA018700B1 (de)
EC (1) ECSP099361A (de)
GT (1) GT200900137A (de)
HR (1) HRP20110503T1 (de)
IL (1) IL198480A0 (de)
MA (1) MA31143B1 (de)
MX (1) MX2009005692A (de)
MY (1) MY145914A (de)
NI (1) NI200900097A (de)
NO (1) NO20092414L (de)
PE (1) PE20081250A1 (de)
PL (1) PL2092069T3 (de)
PT (1) PT2092069E (de)
RS (1) RS51911B (de)
SI (1) SI2092069T1 (de)
SV (1) SV2009003272A (de)
TN (1) TN2009000184A1 (de)
TW (1) TW200839012A (de)
WO (1) WO2008065543A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1660094A4 (de) 2003-08-26 2009-09-16 Univ Colorado Hemmer der serinprotease-aktivität und ihre verwendung bei verfahren und zusammensetzungen zur behandlung von bakterieninfektionen
EP2083081A1 (de) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Zusammensetzungen und Verfahren zur Behandlung von Krankheiten mit FGFR-Fusionsproteinen
BRPI0916904A2 (pt) 2008-08-04 2016-10-11 Fiveprime Therapeutics Inc polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
LT2498799T (lt) 2009-11-13 2016-11-10 Five Prime Therapeutics, Inc. Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
FR2958936A1 (fr) 2010-04-14 2011-10-21 Sanofi Aventis Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
AU2015258172B2 (en) * 2010-11-15 2017-01-12 Five Prime Therapeutics, Inc. Fgfr1 extracellular domain combination therapies
NZ610487A (en) 2010-11-15 2015-03-27 Five Prime Therapeutics Inc Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
PH12013501205A1 (en) 2010-12-23 2013-07-29 Sanofi Sa Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
AR085302A1 (es) * 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
CN102219859B (zh) 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
CA2839917A1 (en) * 2011-06-24 2012-12-27 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
HK1202240A1 (en) 2011-11-14 2015-09-25 戊瑞治疗有限公司 Methods of treating cancer
AU2013202648B2 (en) 2012-01-10 2016-05-19 Konkuk University Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
EA201591324A1 (ru) 2013-01-16 2016-01-29 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
RU2015137610A (ru) 2013-03-06 2017-04-10 Дженентек, Инк. Способы лечения и профилактики лекарственной резистентности злокачественных опухолей
IL289918B2 (en) 2013-03-11 2025-07-01 Genzyme Corp Site-specific antibody-drug conjugation through glycoengineering
US9957313B2 (en) 2013-03-15 2018-05-01 Remegen, Ltd. FGFR-FC fusion proteins and the use thereof
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
BR112015029145A2 (pt) * 2013-05-23 2017-09-19 Glaxosmithkline Ip No 2 Ltd Usos de um domínio extracelular (ecd) de receptor de fator de crescimento de fibroblastos 1 (fgfr1) e métodos de identificação de pacientes
PH12019501393B1 (en) 2013-08-01 2022-09-07 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
US10995148B2 (en) 2014-03-19 2021-05-04 Genzyme Corporation Site-specific glycoengineering of targeting moieties
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
JP7349787B2 (ja) * 2015-11-23 2023-09-25 ファイヴ プライム セラピューティクス インク 癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ
WO2018213304A1 (en) 2017-05-16 2018-11-22 Five Prime Therapeutics, Inc. Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
KR20190065234A (ko) * 2017-11-30 2019-06-11 그리폴스 다이어그노스틱 솔루션즈 인크. 면역 관문 억제제인 pd-1 및 pd-l1에 대한 항체 치료를 모니터링하기 위한 면역분석 및 조작된 단백질
US12448415B2 (en) * 2018-01-04 2025-10-21 Washington University Compositions and methods for inhibition of alphavirus infection
JP7349995B2 (ja) * 2018-01-26 2023-09-25 ジェネンテック， インコーポレイテッド ＩＬ－２２ Ｆｃ融合タンパク質及び使用方法
WO2020206063A1 (en) 2019-04-03 2020-10-08 Genzyme Corporation Anti-alpha beta tcr binding polypeptides with reduced fragmentation

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288856A (en) 1986-11-20 1994-02-22 Pierre Amiguet Method of isolating acid-stable, biologically active proteins
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5750375A (en) * 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5288855A (en) * 1989-01-23 1994-02-22 Farmitalia Carlo Erba Extracellular form of the human fibroblast growth factor receptor
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5153310A (en) * 1989-02-28 1992-10-06 Du Pont Merck Pharmaceutical Company Il-2 analogs containing n-linked glycosylation sites
HU215581B (hu) * 1989-07-06 1999-01-28 Regents Of The University Of California Eljárás fibroblaszt növekedési faktor receptorok előállítására és terápiás alkalmazására
DE69115270T2 (de) * 1990-04-27 1996-06-13 Takeda Chemical Industries, Ltd., Osaka Protein mit fibroblasten-wachstumsfaktor-rezeptoraktivität.
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
EP1403285A1 (de) 1990-07-06 2004-03-31 Gencell S.A. Rezeptoren der Wachstumsfaktoren aus Fibroblasten
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US20020045207A1 (en) * 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6656728B1 (en) * 1999-02-08 2003-12-02 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
US6612152B2 (en) * 1999-05-01 2003-09-02 James E. Keaton Lifting, servicing, and diagnosing automobiles
US6656738B1 (en) * 1999-11-17 2003-12-02 Bae Systems Integrated Defense Solutions Inc. Internal heater for preconcentrator
JP2004504016A (ja) * 2000-06-30 2004-02-12 マキシゲン・エイピーエス ペプチド拡張されたグリコシル化ポリペプチド
CN102311986B (zh) * 2000-10-06 2015-08-19 协和发酵麒麟株式会社 产生抗体组合物的细胞
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040132140A1 (en) * 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
AU2003236018A1 (en) * 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
WO2004029207A2 (en) * 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
WO2005016966A2 (en) 2003-05-16 2005-02-24 Receptor Biologix, Inc. Intron fusion proteins, and methods of identifying and using same
AU2004280066A1 (en) * 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Genomically modified cell
DE102004022895A1 (de) 2004-05-10 2005-12-08 Adam Opel Ag Schallabsorbierendes Verkleidungselement
CN103172731A (zh) 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
US20060223147A1 (en) * 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
EP1871808A2 (de) 2005-03-31 2008-01-02 Xencor, Inc. Fc-varianten mit verbesserten eigenschaften
US20060234347A1 (en) 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
EP1746161A1 (de) * 2005-07-20 2007-01-24 Cytheris Glykosylierte IL-7, Verfahren zur Herstellung und Verwendung davon
EP2083081A1 (de) * 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Zusammensetzungen und Verfahren zur Behandlung von Krankheiten mit FGFR-Fusionsproteinen
AU2006299429B2 (en) 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties

Also Published As

Publication number Publication date
JP2010510801A (ja) 2010-04-08
US8119770B2 (en) 2012-02-21
DK2092069T3 (da) 2011-08-29
CY1112435T1 (el) 2015-12-09
GT200900137A (es) 2011-09-02
BRPI0719290A2 (pt) 2014-02-25
AU2007326985C1 (en) 2014-02-20
RS51911B (sr) 2012-02-29
KR20090102769A (ko) 2009-09-30
SV2009003272A (es) 2010-02-05
EP2092069B1 (de) 2011-05-11
HRP20110503T1 (hr) 2011-08-31
CL2007003411A1 (es) 2008-07-04
SI2092069T1 (sl) 2011-09-30
EA018700B1 (ru) 2013-10-30
MY145914A (en) 2012-05-15
US20100061979A1 (en) 2010-03-11
NO20092414L (no) 2009-08-21
NI200900097A (es) 2010-01-26
US20120195851A1 (en) 2012-08-02
EP2092069A2 (de) 2009-08-26
WO2008065543A2 (en) 2008-06-05
EA200970515A1 (ru) 2009-12-30
PT2092069E (pt) 2011-07-29
PE20081250A1 (es) 2008-10-07
ECSP099361A (es) 2009-06-30
IL198480A0 (en) 2011-08-01
EP2092069B2 (de) 2013-12-18
PL2092069T3 (pl) 2011-10-31
TW200839012A (en) 2008-10-01
AR063975A1 (es) 2009-03-04
CA2668932A1 (en) 2008-06-05
CO6190564A2 (es) 2010-08-19
AU2007326985A1 (en) 2008-06-05
TN2009000184A1 (en) 2010-10-18
US20140030265A1 (en) 2014-01-30
MX2009005692A (es) 2009-10-12
US8481487B2 (en) 2013-07-09
AU2007326985B2 (en) 2013-08-15
WO2008065543A3 (en) 2008-08-14
MA31143B1 (fr) 2010-02-01
CR10777A (es) 2009-07-23

Similar Documents

Publication Publication Date Title
ATE509106T1 (de) Modifizierte lösliche fgf-rezeptor-fc-fusionen mit verbesserter biologischer aktivität
EP2382309A4 (de) Polypeptide mit xylanaseaktivität
BRPI0813909A2 (pt) Seringa com mecanismo de inutilização
EP2382310A4 (de) Polypeptide mit xylanaseaktivität
EP2212807A4 (de) Kollaborative inhaltsbearbeitung
BRPI0918947A2 (pt) proteína de fusão de anticorpo
BRPI0812162A2 (pt) Faixa gástrica hidráulica com reservatório colabável
DK3564267T3 (da) Proteolytisk, spaltbar fusionsprotein med høj molær specifik aktivitet
EP1982167A4 (de) Biosensor
EP1997020A4 (de) Rss-steuerung mit hostmöglichkeit
BRPI0719693A2 (pt) Sal fumarato de (alfa s, beta r)-6-bromo-alfa-[2- (demetilamino)etil]-2-metóxi-alfa-1-naftalenil-beta- fenil-3-quinolinaetanol
BRPI0716272A2 (pt) Compostos arila como ligantes de ppar e sua utilização
BRPI0912988A2 (pt) compostos bicíclicos tendo atividade no receptor cxcr4.
BRPI0815125A2 (pt) Planejador da difusão de segmento
DE602007001361D1 (de) Sphinkterotom mit Zweifachkrümmung
BRPI0812991A2 (pt) Utilização de combustível melhorado
BRPI1011940A2 (pt) redobramento de proteínas usando um estado redox controlado quimicamente.
DE502007001650D1 (de) Turbolader mit katalytische beschichtung
ATE537183T1 (de) Hiv-fusionshemmerpeptide mit verbesserten biologischen eigenschaften
BRPI0921230A2 (pt) agonistas de receptor de neuropeptídeos-2 (y-2r) e usos dos mesmo.
ATE549350T1 (de) Neuropeptid-2-rezeptor-agonisten
EP2017608A4 (de) Biosensor
BRPI0820633A2 (pt) antagonistas de receptores de il-4 muteína modificada
ZA200903134B (en) Modified soluble FGF receptor FC fusions with improved biological activity
EP2017607A4 (de) Biosensor

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2092069

Country of ref document: EP